All In Biotech

Drug Trial Radar · NCT06957691

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Aug 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Shehzad Basaria, M.D.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Astellas Pharma US, Inc.
First posted
May 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims to answer are: * Does fezolinetant improve the frequency and severity of hot flashes? * Does fezolinetant cause any harm to the liver? * Does fezolinetant improve quality of life, sleep quality, fatigue, mood, sexual function, and metabolic parameters? Researchers will compare how people respond to fezolinetant versus a placebo, which does not contain any active medicine. Participants will: * Take fezolinetant or a placebo every day for 4 weeks * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of the number of times and intensity that they experience hot flashes

Conditions

  • Prostate Cancer
  • Prostate Cancer (Adenocarcinoma)
  • Prostate Cancer Metastatic Disease
  • Prostate Cancer Recurrent
  • Prostate Carcinoma
  • Prostate Neoplasm
  • Prostate Adenocarcinoma
  • Prostate Cancer With Bone Metastasis
  • Vasomotor Disturbance
  • Vasomotor Symptoms
  • Vasomotor Symptoms (VMS)
  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
  • Vasomotor Symptoms; Hot Flashes
  • Androgen Deprivation Therapy
  • Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
  • Androgen-deprivation Therapy
  • Hot Flashes
  • Hot Flushes
  • Hot Flushes and/or Sweats

Interventions

  • fezolinetant - reference formulationDrug

    Daily oral administration of fezolinetant at a dose of 45 mg

  • PlaceboDrug

    Daily oral administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Frequency of Vasomotor Symptoms Through Daily Hot Flash Diary from Baseline to 4 WeeksTime frame: From baseline to the end of treatment at 4 weeks.
  2. Hepatic safety, as assessed by measuring liver function testsTime frame: From baseline to the end of treatment at 4 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.